Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 5/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 16/20 | 0.48 |
| ▸ | KDR | P35968 | 4/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3541200 | 1.00 | ABL1 (0.51) | ABL1FGFR1KDRPDGFRAFGFR2 | |
| SCHEMBL3539537 | 1.00 | ABL1 (0.51) | ABL1FGFR1KDRPDGFRAFGFR2 | |
| SCHEMBL3537166 | 1.00 | ABL1 (0.51) | ABL1FGFR1KDRPDGFRAFGFR2 | |
| SCHEMBL5866809 | 0.87 | ABL1 (0.51) | ABL1FGFR1KDRPDGFRAFGFR2 | |
| SCHEMBL5866636 | 0.87 | ABL1 (0.51) | ABL1FGFR1KDRPDGFRAFGFR2 | |
| SCHEMBL5866625 | 0.87 | ABL1 (0.51) | ABL1FGFR1KDRPDGFRAFGFR2 | |
| SCHEMBL5866631 | 0.87 | ABL1 (0.51) | ABL1FGFR1KDRPDGFRAFGFR2 | |
| SCHEMBL5866643 | 0.87 | ABL1 (0.51) | ABL1FGFR1KDRPDGFRAFGFR2 | |
| SCHEMBL5866728 | 0.87 | ABL1 (0.51) | ABL1FGFR1KDRPDGFRAFGFR2 | |
| SCHEMBL6582455 | 0.87 | ABL1 (0.53) | ABL1FGFR1KDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858644-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2010-12-28 | — | — | US | claimed |
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2009-06-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, NR4A1, NR4A2 | ABL1 2642/4885FGFR1 1532/4885KDR 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.